Phentermine/Topiramate in Obese, Diabetic Uric Acid Stone Formers: An Open-Label Randomized Feasibility Trial.

J UrolJun 26, 2026 (epub)
Clinical ResearchNephrologyEndocrinologyInternal Medicine (General)

Benjamin K Canales, Joshua Heiman, Russell Terry et al.

✦ AI-curated · Sources linked

In 30 seconds

This open-label randomized feasibility trial evaluated the effects of phentermine/topiramate on uric acid kidney stone burden in obese, diabetic patients. Among 19 participants, the intervention group experienced a 52% reduction in stone volume compared to an 8.6% increase in controls (P = .10). Per-protocol analysis showed significant results (P = .02).

Key findings

  • Stone volume decreased by 52% in the intervention group versus an 8.6% increase in controls (P = .10).
  • Weight loss was greater in the intervention group (-10.2 kg vs +2.9 kg).
  • The intervention group had a lower hemoglobin A1c reduction (-0.2 vs +0.5).
  • Urinary pH was higher in the intervention group (6.2 vs 5.5).

Why it matters

This study suggests that phentermine/topiramate may effectively reduce uric acid stone burden in obese, diabetic patients, highlighting a potential therapeutic option for managing nephrolithiasis in this population.

Source

PubMed · PMID 42361212

Published in J Urol. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Nephrology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.